Introduction – Addressing Core Industry Pain Points
The global intensive farming landscape faces a persistent challenge: controlling Gram-negative bacterial outbreaks in livestock, poultry, and aquaculture without accelerating antimicrobial resistance (AMR) or violating tightening public-health regulations. Veterinarians, large-scale farms, and regulatory bodies increasingly demand polymyxin B—a cationic cyclic polypeptide antimicrobial produced by microbial fermentation—as a last-resort antibiotic for specific, compliance-driven infection-control scenarios rather than routine broad-spectrum use. However, stricter prescription controls, residue monitoring, withdrawal period enforcement, and AMR surveillance are reshaping market dynamics. Global Leading Market Research Publisher QYResearch announces the release of its latest report “Polymyxin B – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Polymyxin B market, including market size, share, demand, industry development status, and forecasts for the next few years.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart) 】
https://www.qyresearch.com/reports/5997425/polymyxin-b
Market Sizing & Growth Trajectory
The global market for Polymyxin B was estimated to be worth US$ 56.60 million in 2025 and is projected to reach US$ 48.89 million, growing at a CAGR of -2.1% from 2026 to 2032. In 2025, global Polymyxin B production reached approximately 3,773 metric tons (MT) with an average price of about US$ 15 per unit. The average gross profit margin of this product is 1%, reflecting intense pricing pressure and commodity-like competition among Chinese manufacturers. The market is contracting due to AMR governance policies restricting agricultural use, shifting from volume-driven to value-driven, compliance-focused demand.
独家观察 – From Broad-Spectrum to Rescue Therapy: The Polymyxin B Re-Positioning
Polymyxin B is a cationic cyclic polypeptide antimicrobial produced by microbial fermentation (primarily Bacillus polymyxa). Its bactericidal activity stems from binding to lipopolysaccharide (LPS) on the Gram-negative bacterial outer membrane and disrupting membrane integrity. In agriculture, it is used in livestock, poultry, and aquaculture to control infections associated with E. coli, Salmonella, Pasteurella, and Vibrio species. Because polymyxins are classified as “highest priority critically important antimicrobials” (WHO), agricultural use is governed by stricter prescription control, antimicrobial-reduction policies, residue and withdrawal requirements, and ongoing surveillance of resistance risk.
From a discrete manufacturing perspective (batch-based fermentation), polymyxin B production requires: (1) strain maintenance and scale-up (Bacillus polymyxa), (2) fermentation (48-72 hours in optimized media with carbon/nitrogen sources, inorganic salts, trace elements, defoamers), (3) extraction and purification (resin adsorption, membrane separation, solvent precipitation), (4) drying and formulation (API or premix with carriers/binders/stabilizers), and (5) quality control (potency, impurity profiling, endotoxin limits). Batch consistency and traceable quality systems determine regulatory compliance.
Six-Month Trends (H1 2026)
Three trends reshape the market: (1) Chinese production consolidation – Major producers (Shengxue Dacheng, Apeloa, Livzon Group, LKPC, Xellia, Shenghua Biok, Qianjiang Biochemical, Lifecome) face margin compression (1% gross profit) and capacity rationalization; smaller, less compliant producers are exiting; (2) Premix formulation shift – Polymyxin B premix (feed-additive form) is declining faster than API due to China’s ban on colistin (polymyxin E) as a feed additive (2017) and similar pressures on polymyxin B; injectable/water-soluble formulations for veterinary prescription use retain demand; (3) Export market contraction – EU and other markets have tightened import residues limits (MRLs) for polymyxins, reducing export volumes from China (estimated 15-20% decline since 2024).
User Case Example – Compliance-Driven Use, Intensive Swine Operation, China
A large-scale swine operation in Shandong Province (50,000 sows, integrated farrow-to-finish) implemented a veterinary antimicrobial stewardship program in January 2025, restricting polymyxin B use to confirmed colistin-resistant E. coli outbreaks with susceptibility testing. From January 2025 to March 2026: polymyxin B use decreased by 68% (from 2.4 kg/1,000 pigs to 0.77 kg/1,000 pigs); treatment success rate for targeted outbreaks remained 89%; overall antimicrobial use intensity (mg/PCU) decreased by 41%; no polymyxin B residues detected in surveillance testing. The farm achieved compliance with China’s “Anti-microbial Use Reduction Action Plan” and maintained productivity metrics.
Technical Challenge – Fermentation Yield Variability & Impurity Control
A key technical challenge in polymyxin B manufacturing is fermentation yield variability (range 3-8 g/L depending on strain optimization, media quality, and process control). Lower yields directly impact cost of goods—critical given 1% gross margins. Additionally, purification must remove fermentation-related impurities (including related polypeptides, residual media components, and bacterial endotoxins) to meet veterinary pharmacopoeial standards. Leading manufacturers employ strain improvement programs (including mutagenesis and selection) and process analytical technology (PAT); smaller producers with less sophisticated control face higher batch rejection rates (5-10% vs. <2% for leaders).
Regulatory & Policy Landscape
Two developments impact the market: (1) China’s AMR Action Plan update (2025-2026) – New targets for veterinary antimicrobial use reduction (30% reduction in mg/PCU by 2027 vs. 2023 baseline) and mandatory susceptibility testing before polymyxin use in designated large farms; (2) EU MRL revisions (March 2026) – Lowered maximum residue limits for polymyxin B in swine and poultry tissues (muscle, liver, kidney, fat), requiring extended withdrawal periods (from 7 to 14 days) and increased testing costs for exporters.
Market Dynamics: Drivers, Constraints, and Downstream Shifts
Drivers: Rising stocking density, disease pressure, and stress factors in intensive farming sustain rigid need for rapid control of Gram-negative outbreaks. Large-scale farms invest more in biosecurity, treatment protocols, and traceable medication management. Constraints: Tightening AMR governance narrows polymyxin use boundaries; residue compliance and withdrawal enforcement add operational risk; batch variability or improper use amplifying resistance concerns and public scrutiny can quickly escalate channel and brand risks. Downstream shifts from “treating disease” toward integrated prevention-first strategies. Decision-making increasingly relies on pathogen evidence, susceptibility insights, and stratified treatment pathways. Large farms prefer compliant, traceable supply, consistent formulation quality, and convenient on-site use, coordinating with vaccines, microbiome-based solutions, husbandry management, and environmental sanitation.
Segmentation Summary
The Polymyxin B market is segmented as below:
Segment by Type – Polymyxin API (bulk active pharmaceutical ingredient for formulation), Polymyxin Premix (feed-additive, declining segment)
Segment by Application – Pigs (largest segment, swine dysentery, post-weaning diarrhea), Chickens (poultry, colibacillosis), Cows (mastitis, calf diarrhea)
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
